Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the national biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings like the American Society of Clinical Oncology and broke news about the industry's top companies, including Amgen, Genentech, and Biogen Idec. His stories appeared in The New York Times, Los Angeles Times, and International Herald Tribune. From 2001 to 2006, his passionate coverage of the biotechnology industry won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Gerald Loeb Award, Scripps Howard National Journalism Award, and the Sigma Delta Chi prize from the Society of Professional Journalists, and was nominated for the Pulitzer Prize in public service. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke runs marathons, climbs mountains and roots for the Green Bay Packers.Agios Pharmaceuticals is moving full steam ahead. The company has moved into a new 21,000-square-foot space in Cambridge, MA, that it says is the world’s largest lab devoted to studying how... Read more »
(Update: Antigenics stock surged 13 percent today after this news appeared.)
Antigenics is offering a glimmer of hope for patients with terminal brain tumors. The Lexington, MA-based biotech company said its... Read more »
It’s a sad day for Seattle biotech. One of the charismatic pioneers of the local life sciences cluster, Bruce Carter, is retiring from his job as CEO of ZymoGenetics.
“I’m... Read more »
Ask Ironwood Pharmaceuticals CEO Peter Hecht what he’s trying to accomplish in the next six to 12 months, and he doesn’t tiptoe around. “We’re trying to build the next great pharmaceutical... Read more »
Accelerator’s newest startup could, if it wanted to, make a version of marijuana that wouldn’t give people the munchies. Seattle-based GPC-Rx isn’t going to do that, but it is using sophisticated... Read more »
Infinity Pharmaceuticals, a Cambridge, MA-based developer of cancer drugs, got a significant boost today. It signed a partnership worth $75 million upfront from Stamford, CT-based Purdue Pharma, the maker of the... Read more »
CombinatoRx, the Cambridge, MA-based biotech company, said this afternoon it is cutting 30 more jobs, which means it has now eliminated two-thirds of its staff since its lead drug candidate for... Read more »
Geospiza, a Seattle-based maker of software to help researchers keep track of massive amounts of genomic data, said today it has acquired the Genesifter technology created by Seattle-based VizX Labs. Terms... Read more »
Immune Design, the Seattle-based vaccine development company, has obtained a worldwide exclusive license to develop a vaccine-boosting compound invented at the Infectious Disease Research Institute (IDRI). The technology, a glycopyranosyl lipid... Read more »
We scored exclusive interviews with a couple of biotech industry leaders this week, and heard their views on some of the most intriguing technologies they see emerging in Seattle and around... Read more »
(Update: The fourth paragraph includes a statement from Targanta about the panel’s vote.)
Targanta Therapeutics was dealt a blow late this afternoon. A panel of expert advisers to the FDA voted... Read more »
One of Seattle’s best-known technology investors, Tom Alberg of Madrona Venture Group, had a conversation a couple years ago with David Brewster, the founding editor of Seattle Weekly, about how the... Read more »
Get ‘em while they’re young. It’s true of the folks who market breakfast cereals, and also in the world of philanthropy.
The Fred Hutchinson Cancer Research Center has a reputation as... Read more »
David Miller, the co-founder and CEO of Biotech Stock Research, an independent stock research firm in Seattle, has filed paperwork to run for the Seattle City Council. Miller plans to... Read more »
Chris Rivera, a longtime biotech industry executive with experience in sales and marketing, has been hired as the new president of the Washington Biotechnology & Biomedical Association, the state’s trade group... Read more »
Zacharon Pharmaceuticals has gotten a shot of cash to develop a new class of drugs. The San Diego company said it has raised $3.5 million in a Series A venture round... Read more »
Geospiza, a Seattle-based maker of software to help researchers analyze reams of genomic data, said today it has sold its FinchLab product to the Molecular Genetics Core Facility shared by Children’s... Read more »
Todd Patrick is one of those rare people in the pharmaceutical business who can say he built a successful career as a vaccines entrepreneur. He was the president of ID Biomedical... Read more »
These are grim times for many industries, and the life sciences are no exception. Most of these enterprises depend on the ability to raise fresh investment capital on a regular basis,... Read more »
Genzyme said today the FDA plans to allow it to market alglucosidase alfa (Myozyme) made in a large-scale 2000 liter bioreactor. The Cambridge, MA-based biotech company (NASDAQ: GENZ) said it... Read more »
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.